{
    "clinical_study": {
        "@rank": "117755", 
        "arm_group": [
            {
                "arm_group_label": "Coagulation Factor VIIa (Recombinant): 75 \u00b5g/kg", 
                "arm_group_type": "Active Comparator", 
                "description": "Coagulation Factor VIIa (Recombinant): 75 \u00b5g/kg for 3 months"
            }, 
            {
                "arm_group_label": "Coagulation Factor VIIa (Recombinant): 225 \u00b5g/kg", 
                "arm_group_type": "Active Comparator", 
                "description": "Coagulation Factor VIIa (Recombinant) : 225 \u00b5g/kg for 3 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the safety,  efficacy and pharmacokinetics  of 2\n      separate dose regimens (75\u00b5g/kg and 225 \u00b5g/kg) of Coagulation Factor VIIa (Recombinant) for\n      the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor\n      VIII/IX"
        }, 
        "brief_title": "A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hemophilia A With Inhibitors", 
            "Hemophilia B With Inhibitors"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemophilia B", 
                "Hemophilia A"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  be male with a diagnosis of congenital hemophilia A and/or B of any severity\n\n          -  have one of the following:\n\n          -  a positive inhibitor test Bethesda Unit (BU) \u2265 5 (as confirmed at screening by the\n             institutional lab), OR\n\n          -  a BU<5 but expected to have a high anamnestic response to FVIII or       FIX,   as\n             demonstrated from the subject's medical history, precluding the use of Factor VIII or\n             IX products to treat bleedings, OR\n\n          -  a BU<5 but expected to be refractory to increased dosing of FVIII or FIX, as\n             demonstrated from the subject's medical history, precluding the use of Factor VIII or\n             IX products to treat bleedings\n\n          -  be 12 years or older, up to and including 75 years of age (NOTE: different age\n             restrictions may apply per local regulation and/or ethical considerations)\n\n          -  have at least 3 bleeding episodes of any severity in the past 6 months be capable of\n             understanding and willing to comply with the conditions of the protocol\n\n          -  have read, understood and provided written informed consent (patient and/or\n             parent(s)/legal guardian(s) if <18 years of age)\n\n        Exclusion Criteria:\n\n          -  have any coagulation disorder other than hemophilia A or B\n\n          -  be immuno-suppressed (i.e., the patient should not be receiving systemic\n             immunosuppressive medication, cluster of differentiation 4 (CD4) counts at screening\n             should be >200/\u00b5l)\n\n          -  have a known allergy or hypersensitivity to rabbits\n\n          -  have platelet count <100,000/mL\n\n          -  have had within one month prior to first administration of the study drug in this\n             study a major surgical procedure (e.g. orthopedic, abdominal)\n\n          -  have received an investigational drug within 30 days of the first study drug\n             administration, or is expected to receive such drug during participation in this\n             study\n\n          -  have a clinically relevant hepatic (AST and/or alanine aminotransferase (ALT) >3\n             times the upper limit of normal) and/or renal impairment (creatinine >2 times the\n             upper limit of normal)\n\n          -  have a history of arterial and/or venous thromboembolic events (such as myocardial\n             infarction, ischemic strokes, transient ischemic attacks, deep venous thrombosis or\n             pulmonary embolism) within 2 years prior to first dose of study drug, or current New\n             York Heart Association (NYHA) functional classification score of stage II -IV\n\n          -  have an active malignancy (those with non-melanoma skin cancer are allowed)\n\n          -  have any life-threatening disease or other disease or condition which, according to\n             the investigator's judgment, could imply a potential hazard to the patient, interfere\n             with the trial participation or trial outcome (e.g., a history of non-responsiveness\n             to bypassing products)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020369", 
            "org_study_id": "RB-FVIIa-006-13"
        }, 
        "intervention": {
            "arm_group_label": [
                "Coagulation Factor VIIa (Recombinant): 75 \u00b5g/kg", 
                "Coagulation Factor VIIa (Recombinant): 225 \u00b5g/kg"
            ], 
            "description": "A cross over design to assess the efficacy of 2 separate dose regimens (75\u00b5g/kg and 225 \u00b5g/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX", 
            "intervention_name": "Coagulation Factor VIIa (Recombinant)", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 25, 2014", 
        "location": {
            "contact": {
                "email": "LLacanilao@mednet.ucla.edu", 
                "last_name": "Lucy Lacanilao", 
                "phone": "213-742-1402"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90007"
                }, 
                "name": "Orthopaedic Hemophilia Treatment Center"
            }, 
            "investigator": {
                "last_name": "Doris Quon", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX", 
        "other_outcome": [
            {
                "description": "Based on Coagulation Factor VIIa (Recombinant),  binding antibody levels", 
                "measure": "Immunogenicity assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose, 6 week, 12 weeks, 24 weeks then every 12 weeks and end of study visit"
            }, 
            {
                "description": "Based on plasma concentrations of Coagulation Factor VIIa (Recombinant)", 
                "measure": "Pharmacokinetic assessment", 
                "safety_issue": "No", 
                "time_frame": "7 timepoints from pre-dosing on Day 1 up to 8 hours"
            }
        ], 
        "overall_contact": {
            "email": "denise.tilton@revobiologics.com", 
            "last_name": "Denise Tilton, RN, MHA", 
            "phone": "508-370-5257"
        }, 
        "overall_contact_backup": {
            "email": "meg.carini@revobiologics.com", 
            "last_name": "Meg Carini, LPN, BS, CCRA", 
            "phone": "508-370-5258"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "No additional hemostatic product required after12 hours of first dose.", 
            "measure": "Bleeding episode treatment success", 
            "safety_issue": "No", 
            "time_frame": "12 hours after first administration of study drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020369"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Patients shall rate the treatment of each bleeding episode.  If treatment occurs under direct supervision of treating physician, then physician shall rate the response.  Ratings based on a four point scale:Excellent, Good, Moderate, None", 
            "measure": "Time to bleeding success", 
            "safety_issue": "No", 
            "time_frame": "at 12 hours"
        }, 
        "source": "rEVO Biologics", 
        "sponsors": {
            "collaborator": {
                "agency": "Laboratoire fran\u00e7ais de Fractionnement et de Biotechnologies", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "rEVO Biologics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}